Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Twelve interventional live cases to use Toshiba's Infinix DP-i X-ray system at NCVH conference

Enabling physicians to perform a range of interventional procedures, Toshiba America Medical Systems, Inc.'s InfinixTM DP-i X-ray system provides clinicians with the ability to transition between cardiac and peripheral work seamlessly.

1 Jun 2011

Suberoylanilide hydroxamic acid holds promise against familial frontotemporal dementia

A drug already approved for people with cancer shows early potential as a therapy for a common form of dementia, UT Southwestern Medical Center researchers report.

1 Jun 2011

Study: E-waste linked to adverse effects on human health

In addition to its damaging effect on the environment and its illegal smuggling into developing countries, researchers have now linked e-waste to adverse effects on human health, such as inflammation and oxidative stress - precursors to cardiovascular disease, DNA damage and possibly cancer.

31 May 2011

Study on entire Swedish population affirms significance of hereditary factors for venous thromboembolism

Venous thromboembolism (VTE) is the third most common type of cardiovascular disease after coronary heart disease and stroke. Researchers at the Centre for Primary Health Care Research in Malmö have mapped the significance of hereditary factors for venous thromboembolism in the entire Swedish population by studying the risk of VTE in children of parents with VTE compared with the children of parents who have not had VTE.

30 May 2011

'Ultra-bad' cholesterol increases risk of heart disease in people with type 2 diabetes

Scientists from the University of Warwick have discovered why a newly found form of cholesterol seems to be 'ultra-bad', leading to increased risk of heart disease. The discovery could lead to new treatments to prevent heart disease particularly in people with type 2 diabetes and the elderly.

30 May 2011

Obesity and insulin resistance are a greater risk for fatty liver than previously thought

Being overweight and resistant to insulin constitute a greater risk for fatty liver than was previously thought, according to a study from Linköping University in Sweden that is now being published in the journal Annals of Medicine.

30 May 2011

Lipidomic profiling can lead to better and earlier prediction of major diseases

Studying the genetic make-up of different varieties of lipids in the blood plasma of an individual can lead to a better and earlier prediction of diseases such as diabetes, atherosclerosis, and heart disease, two researchers will tell the annual conference of the European Society of Human Genetics today.

30 May 2011

Cholesterol drug Niaspan fails to protect heart: Study

According to researchers at the National Heart, Lung, and Blood Institute (NHLBI), increasing the dose of niacin to patients with heart disease who are already taking a cholesterol-lowering statin does nothing extra to prevent heart attacks and strokes. Approximately one out of seven Americans have high blood cholesterol, a main risk factor in heart disease, which kills some 800,000 people in the United States annually.

29 May 2011

Ultra bad cholesterol

Bad cholesterol, known as LDL is known to be sticky but this ultra –bad called MGmin-LDL is found to be stickier meaning it's more likely to attach to arterial walls. This is more dangerous because when LDL attaches to artery walls it forms fatty plaques that cause coronary heart disease (CHD). As fatty plaques grow, they narrow the arteries and reduce blood flow and also may trigger a stroke or heart attack. CHD is the most common type of heart disease and kills almost 450,000 Americans each year.

29 May 2011

High blood pressure becoming more common in young adults: Study

According to a new study about one in five young adults may have high blood pressure. The researchers from the University of North Carolina at Chapel Hill analyzed blood pressure data from the National Longitudinal Study of Adolescent Health, called Add Health, and compared it with data from the National Health and Nutrition Examination Survey, commonly referred to as NHANES. They focused specifically on the information about adults age 24 to 32.

29 May 2011

Efficacy of Abbott cholesterol drug in question

A latest study has found that using medication to raise good cholesterol while lowering the bad does NOT translate into fewer adverse cardiovascular events like heart attacks and strokes. The study was revealed Thursday by the National Institutes of Health and it found that high dosages of Abbott Laboratories' Niaspan failed to prevent heart attacks and boosted the likelihood of a stroke when combined with the popular generic cholesterol pill Simvastatin, also known under the brand name Zocor.

29 May 2011

Interim analysis of AIM-HIGH study affirms positive impact of Niaspan on HDL and triglyceride lipid values

The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), disclosed results from an interim analysis of the AIM-HIGH clinical trial.

27 May 2011

Study: Cardiovascular disease may be under treated in rheumatoid arthritis patients

Results of a study, involving 98,454 patients demonstrated that at 30 days following their first heart attack, RA patients were approximately 20% less likely to be prescribed standard MI treatments, such as statins and betablockers, compared to healthy patients.

27 May 2011

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

The National Heart, Lung, and Blood Institute of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned. The trial found that adding high dose, extended-release niacin to statin treatment in people with heart and vascular disease, did not reduce the risk of cardiovascular events, including heart attacks and stroke.

27 May 2011

Gout drug success for Novartis

Novartis AG's new gout therapy drug gives patients better pain relief and significantly cuts the risk of new attacks say two late stage studies. The studies show that more than 450 patients taking Ilaris, or ACZ885, had less pain and the risk of new attacks were reduced by up to 68 percent compared to those taking an injectable steroid to treat gouty arthritis attacks, which can last for a week or more.

26 May 2011

Study links decrease in U.S. workplace physical activity with obesity epidemic

In a new study conducted at the Pennington Biomedical Research Center, scientists have found that the decrease in workplace physical activity over the past fifty years is a significant contributor to the obesity epidemic.

26 May 2011

New Hypertension Management Program study results revealed at ASH scientific meeting

High blood pressure - the silent killer - is taking a hit from a new, ground-breaking treatment program from the Heart and Stroke Foundation of Ontario.

26 May 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Ardea Biosciences, Inc. announced that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, UK.

26 May 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA plus prednisone compared to patients treated with prednisone plus placebo.

26 May 2011

Comtex SmarTrend ranks POZEN as second most efficient pharmaceutical company

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that Comtex SmarTrend has ranked POZEN as the second most efficient company in the pharmaceutical industry.

25 May 2011

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Twelve interventional live cases to use Toshiba's Infinix DP-i X-ray system at NCVH conference

Suberoylanilide hydroxamic acid holds promise against familial frontotemporal dementia

Study: E-waste linked to adverse effects on human health

Study on entire Swedish population affirms significance of hereditary factors for venous thromboembolism

'Ultra-bad' cholesterol increases risk of heart disease in people with type 2 diabetes

Obesity and insulin resistance are a greater risk for fatty liver than previously thought

Lipidomic profiling can lead to better and earlier prediction of major diseases

Cholesterol drug Niaspan fails to protect heart: Study

Ultra bad cholesterol

High blood pressure becoming more common in young adults: Study

Efficacy of Abbott cholesterol drug in question

Interim analysis of AIM-HIGH study affirms positive impact of Niaspan on HDL and triglyceride lipid values

Study: Cardiovascular disease may be under treated in rheumatoid arthritis patients

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

Gout drug success for Novartis

Study links decrease in U.S. workplace physical activity with obesity epidemic

New Hypertension Management Program study results revealed at ASH scientific meeting

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

Comtex SmarTrend ranks POZEN as second most efficient pharmaceutical company

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in